William Mack & Associates’s Helus Pharma Inc. Common Stock HELP Stock Holding History

William Mack & Associates’s Portfolio HELP Stock Details HELP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$13	Buy	+1	New	+$10	﹤0.01%	865

Other funds holding HELP

DCF Advisers Greenwich, Connecticut $444M AUM 151.5% 1-Year Est. Return

Nan Fung Group Holdings Kai Tak, Hong Kong $150M AUM 39.16% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return

DMKJ

David M. Knott Jr $183M AUM 73.23% 1-Year Est. Return

Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return

Picton Mahoney Asset Management Toronto, Ontario, Canada $14.8B AUM 38.11% 1-Year Est. Return

William Mack & Associates's HELP Position: Q3 2026 in Review

William Mack & Associates opened a new position in Helus Pharma Inc. Common Stock (HELP) in Q3 2026: 1 share worth $13. The stake represents ﹤0.01% of the portfolio and ranks #865 among its holdings.

73 funds tracked by Wall St. Rank hold HELP as of Q3 2026.

William Mack & Associates held 1 share of Helus Pharma Inc. Common Stock worth $13 as of Q3 2026.
Helus Pharma Inc. Common Stock was a new William Mack & Associates position in Q3 2026.
Helus Pharma Inc. Common Stock made up ﹤0.01% of William Mack & Associates's portfolio in Q3 2026, its #865 holding.
73 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q3 2026.

Based on William Mack & Associates's 13F filing for Q3 2026, filed 27 Oct 2026.